Hiren G Patel

US Patent:

6458957, Oct 1, 2002

Filed:

Jul 12, 2000

Appl. No.:

09/614295

Inventors:

Anup K. Ray - Staten Island NY
Hiren Patel - Edison NJ
Shilpa V. Merai - North Brunswick NJ
Mahendra R. Patel - East Brunswick NJ

Assignee:

Geneva Pharmaceuticals, Inc. - Broomfield CO

International Classification:

C07D21126

US Classification:

546233, 546262, 546267, 546340, 564169, 544175, 544386, 544399

Abstract:

This disclosure relates to the use of ,-dibromo--chloroacetophenone compounds as intermediates for the preparation of aromatic carbonyl compounds, especially aromatic amides. The compound 2,5-bis(2,2,2-trifluoroethoxy)-,-dibromo--chloroacetophenone is especially useful as an intermediate for the preparation of flecainide, a known pharmaceutical.

US Patent:

6548492, Apr 15, 2003

Filed:

Oct 27, 2000

Appl. No.:

09/698808

Inventors:

Anthony Al-Dehneh - Elmwood Park NJ
William A. Hunke - Harleysville PA
Kathleen J. Illig - Phoenixville PA
Anand Kanike - Lansdale PA
Hiren Patel - Parsippany NJ
Scott D. Reynolds - Pekiomenville PA
Stelios C. Tsinontides - Ambler NJ

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

C07D48704

US Classification:

51421013, 540350

Abstract:

A novel process for preparing a stabilized, lyophilized carbapenem, antibiotic formulation suitable for intravenous administration to patients in need thereof, wherein the active ingredient is of formula II: The process entails compounding a unstable, monosodium salt carbapenem with a sodium bicarbonate solution at a temperature range of from about 0Â to about 5Â C. while maintaining a pH between about 7. 0 and about 8. 0, filtering the resultant solution, bottling under sterile conditions, and lyophilizing to produce the formulation.

US Patent:

6586598, Jul 1, 2003

Filed:

May 8, 2002

Appl. No.:

10/140638

Inventors:

Anup K. Ray - Staten Island NY
Hiren Patel - Edison NJ
Shilpa V. Merai - North Brunswick NJ
Mahendra R. Patel - East Brunswick NJ

Assignee:

Geneva Pharmaceuticals, Inc. - Broomfield CO

International Classification:

C07D21132

US Classification:

546220, 546233, 546337, 568308, 568309, 568335

Abstract:

This disclosure relates to the use of ,-dibromo--chloroacetophenone compounds as intermediates for the preparation of aromatic carbonyl compounds, especially aromatic amides. The compound 2,5-bis(2,2,2-trifluoroethoxy)-,-dibromo--chloroacetophenone is especially useful as an intermediate for the preparation of flecainide, a known pharmaceutical.

US Patent:

6962924, Nov 8, 2005

Filed:

Jul 17, 2003

Appl. No.:

10/621670

Inventors:

Anup Kumar Ray - Staten Island NY, US
Hiren Patel - Edison NJ, US
Mahendra R Patel - East Brunswick NJ, US

Assignee:

Sandoz AG - Basel

International Classification:

A61K031/4545
A61K031/445
C07D401/04
C07D401/08
A61P037/08

US Classification:

514290, 546 93

Abstract:

This invention provides a process of preparation of novel polymorphic hemifumarate salts of 8-chloro-6,11-dihyfro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclohepta[1,2-b]pyridine, hereinafter called “desloratadine”. These polymorphic salt forms show much higher solubility in water and also in protic organic solvents compare to the parent desloratadine. The process of preparing the polymorphic forms comprising:.

US Patent:

7125563, Oct 24, 2006

Filed:

Apr 12, 2002

Appl. No.:

10/120501

Inventors:

Harish B. Pandya - Piscataway NJ, US
Hiren Patel - Parsippany NJ, US

Assignee:

DAVA Pharmaceuticals, Inc. - Fort Lee NJ

International Classification:

A61K 9/22
A61K 9/24

US Classification:

424468, 424464, 424472

Abstract:

An extended release tablet comprising a core including albuterol sulfate and extended release agent; and an extended release coating on the core to provide for sustained release of the albuterol sulfate.

US Patent:

7297789, Nov 20, 2007

Filed:

May 30, 2003

Appl. No.:

10/449643

Inventors:

Hiren V. Patel - Fords NJ, US
Anup K. Ray - Staten Island NY, US
Pramod B. Patel - Bordentown NJ, US
Mahendra R. Patel - East Brunswick NJ, US

Assignee:

Sandoz, Inc. - Princeton NJ

International Classification:

A61K 31/55
C07D 487/02
A61P 25/18

US Classification:

540557, 514220

Abstract:

A process for the preparation of polymorph Form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine, or olanzapine.

US Patent:

8536305, Sep 17, 2013

Filed:

Sep 27, 2007

Appl. No.:

11/904422

Inventors:

Anup K Ray - Staten Island NY, US
Hiren V Patel - Fords NJ, US
Johannes Ludescher - Breitenbach, AT
Mariappan Anbazhagan - Monmouth Junction NJ, US
Mahendra R Patel - Milltown NJ, US
Ingolf Macher - Woergl, AT

Assignee:

Sandoz AG - Basel

International Classification:

A61K 38/00
C07K 1/00
C07K 2/00

US Classification:

530333, 514 11, 530300, 530335, 530336, 530337, 530344, 530350

Abstract:

The present invention relates to an improved process for preparing a polypeptide or pharmaceutically acceptable salt thereof comprising L-tyrosine, L-alanine, L-glutamate, and L-lysine. The polypeptide or pharmaceutically acceptable salt thereof is preferably glatiramer acetate. The process comprises: (a) polymerizing a mixture of N-carboxyanhydride of L-tyrosine, N-carboxyanhydride of L-alanine, N-carboxyanhydride of a protected L-glutamate and N-carboxyanhydride of a protected L-lysine, in a polar aprotic solvent in the presence of an initiator, to form a protected polypeptide; (b) admixing an acid with the protected polypeptide formed in Step (a) and a solvent, to form a product; and (c) admixing a substance selected from the group consisting of an alkali or alkaline earth metal hydroxide, a carbonate, a hydrogencarbonate, and mixtures thereof, with the product formed in Step (b), and a solvent or a mixture of a solvent and water, to form a deprotected polypeptide or a pharmaceutically acceptable salt thereof.

US Patent:

20030139606, Jul 24, 2003

Filed:

Nov 5, 2002

Appl. No.:

10/287936

Inventors:

Anup Ray - Staten Island NY, US
Hiren Kumar Patel - Fords NJ, US
Mahendra Patel - East Brunswick NJ, US

International Classification:

C07D261/18

US Classification:

548/248000

Abstract:

A process for preparing 5-methylisoxazole-4-carboxylic-(4′-trifluoromethyl)-anilide comprising: (a) reacting ethylacetoacetate, triethylorthoformate, and acetic anhydride at a temperature of from about 75 C. to about 150 C., to form ethyl ethoxymethyleneacetoacetic ester; (b) combining the ethyl ethoxymethyleneacetoacetic ester with sodium acetate or a salt of trifluoroacetic acid in the presence of hydroxylamine sulfate at a temperature of from about -20 C. to 10 C., to form ethyl-5-methylisoxazole-4-carboxylate; (c) reacting the ethyl-5-methylisoxazole-4-carboxylate with a strong acid to form 5-methylisoxazole-4-carboxylic acid; (d) reacting the crystallized 5-methylisoxazole-4-carboxylic acid with thionyl chloride to form 5-methylisoxazole-4-carbonyl chloride; and (e) reacting the 5-methylisoxazole-4-carbonyl chloride with trifluoromethyl aniline and an amine base at a temperature of from about 0 C. to about 50 C. to form 5-methylisoxazole-4-carboxylic-(4′-trifluoromethyl)-anilide. The process of the invention is especially advantageous for preparing 5-methylisoxazole-4-carboxylic-(4′-trifluoromethyl)-anilide, since the process: (1) eliminates or reduces the formation of the by-product 2-cyanoacetoacetic-1-(4′-trifluoromethyl)-anilide (CATA), generally as low as 0.0006%; (2) eliminates or reduces the formation of isomeric impurity ethyl-3-methyisoxazole-4-carboxylate and its corresponding acid as low as 0.1%, (3) produces a high quality of 5-methylisoxazole-4-carboxylic-(4′-trifluoromethyl)-anilide generally having 99.8-100% HPLC potency; and (4) does not require distillation of the isoxazole ester.